

974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003

Supplementary Materials for

Reducing Ischemia Kidney Injury Through the Application of a Synchronization Modulation Electric Field to Maintain Na⁺/K⁺-ATPase Functions

The PDF file includes:
Materials and Methods
Figs. S1 to S3
References (57–67)

Materials and Methods

Composition of the solutions

Relaxing solution: 120mM Potassium Glutamate, 5mM K₂PIPES, 1mM MgSO₄, 0.1mM K₂EGTA.

External solution: 3.5mM 3,4-Diaminopyridine (3,4-DAP), 86mM NaCl, 10mM CsCl, 4mM KCl, 2.15mM Na₂HPO₄, 0.85mM NaH₂PO₄·H₂O, 1.8mM CaCl₂, 1.5mM BaCl₂·2H₂O, 1μM Tetrodotoxin (TTX). The pH of the solution was adjusted to 7.10 via HCl at room temperature. Final [K]_o was ~4mM and [Na]_o~90mM.

Internal solution (at physiological condition): 58mM K-glutamate, 6.8mM MgSO₄ · 7H₂O, 5mM MOPS, 20mM EGTA, 10mM CsOH, 4mM Na₂-Creatine phosphate, 5mM 5'-ATP-K₂. The pH of the solution was adjusted to 7.30 via KOH at room temperature.

Washing-out solution (Internal solution lack of ATP molecules): 68mM K-glutamate, 6.8mM MgSO₄, 5mM MOPS, 20mM EGTA, 4mM K₂HPO₄, 10mM CsOH, 200nM Antimycin A. The pH of the solution was adjusted to 7.30 via KOH at room temperature.

MOPS: 3-(N-Morpholino) propanesulfonic acid; EGTA: Ethylene glycol-bis (2-aminoethylether)- N,N,N',N'-tetraacetic acid.

Urinary flow and Na⁺ excretion under the physiological conditions

Sprague-Dawley rats were anesthetized with 70 mg/kg inactin (i.p.) and 50 mg/kg ketamine (i.m.) and then placed on a temperature-controlled table with the body temperature maintained at 37 °C throughout the experiment. The surgical procedure was similar as described previously (65, 66). Both the left and right ureters were catheterized

1004 with PE-50 tubing to collect urine from each kidney separately. For the urinary flow and
1005 Na⁺ excretion in response to 3rdgen-SMEF under physiological conditions, the
1006 decelerating 3rdgen-SMEF was applied to one kidney using the electrode arrays and the
1007 other kidney as control. After a 30-min equilibration period, the urine was collected in
1008 Eppendorf tubes for 30 minutes as baseline. Then, the decelerating 3rdgen-SMEF was
1009 turned on and urine was collected for another 30 minutes. The decelerating 3rdgen-SMEF
1010 was then switched off and the urine was collected for another 30 minutes from both
1011 kidneys. Sodium concentrations were measured with a Flame Photometer (BWB
1012 Technologies).

1013 **Urinary flow in response to acute volume challenge**

1014 Acute volume expansion was performed as we previously reported (57, 58). Briefly,
1015 SD rats were anesthetized with inactin (70 mg/kg, i.p.) and ketamine (50 mg/kg, i.m.). The
1016 carotid artery was cannulated to monitor the mean arterial pressure (MAP). Saline
1017 (0.9%NaCl) with 2% bovine serum albumin (BSA) was intravenously infused at a rate of
1018 6 ml/hour through the jugular vein. The accelerating-3rdgen-SMEF was applied to both
1019 kidneys throughout the experiment with the frequency increased from 50 Hz to 300Hz.
1020 The potential difference applied between each pair of electrodes was 100 mV.

1021 After 30-min equilibrium, the urine samples (collected from both ureter catheters) were
1022 collected continuously for 30 minutes before acute volume expansion as the baseline.
1023 Then the rats were given an acute volume challenge by an intravenous bolus of 0.9%
1024 normal saline (0.9%NaCl, 5% body weight, i.v.) using an infusion pump. For the treatment
1025 group, the accelerating-3rdgen-SMEF was simultaneously turned on. The group of rats
1026 without the application of electric field served as controls. Urine samples were collected
1027 at 30 min intervals for 90 minutes after acute volume expansion for both control and
1028 treatment groups. Then the accelerating-3rdgen-SMEF was turned off and the urine
1029 samples were collected for additional 60 minutes. At the end of the experiment, both
1030 kidneys were removed, drained, and weighed.

1031 **Plasma creatinine (Pcr) and Neutrophil gelatinase-associated lipocalin (NGAL)** 1032 **measurement**

1033 For Pcr concentration measurements, blood (20µl) was collected into a heparinized
1034 micro capillary tube from the tail vein and was immediately centrifuged to separate blood

1035 cells from plasma. Plasma (10µl) was collected into an Eppendorf tube and stored in a -
1036 80°C freezer until analyzed. Pcr concentrations were measured with HPLC-mass
1037 spectrometry at O'Brien Center at the University of Alabama at Birmingham.

1038 Plasma NGAL levels were measured with an ELISA kit (R&D Systems, MLCN20)
1039 following the manufacturer's instructions.

1040 **Glomerular filtration rate (GFR) measurement in conscious mice**

1041 GFR was measured in conscious C57BL/6J mice using a single bolus intravenous
1042 injection of fluorescein isothiocyanate-sinistrin (FITC-sinistrin) (Fresenius Kabi Austria
1043 GmbH) as described recently with a modification (62, 63). Briefly, the FITC-sinistrin
1044 solution (4 µl/g body weight) was injected via retro orbital sinus of the mice under light
1045 anesthesia with isoflurane. Blood was collected (about 5 µl/each) from a small nick at the
1046 end of the tail into a heparinized microcapillary tube at 3, 7, 10, 15, 35, 55, 75 and 90 min
1047 after injection. The blood samples were centrifuged, and plasma fractions (2 µl/each)
1048 were collected. FITC-sinistrin fluorescent intensities of the plasma samples were
1049 measured using a plate reader (Cytation5, BioTek) with 485-nm excitation and 538-nm
1050 emission. GFR was calculated using a two-compartment model of two-phase exponential
1051 decay (GraphPad Prism) and was presented as microliters per minute (µl.min⁻¹).

1052 **Histology, Immunofluorescence and TUNEL staining on kidney tissue sections**

1053 Paraffin embedded kidney samples were sectioned into 4-µm slices. Histological
1054 morphology and the degree of renal tubular injury were evaluated with periodic acid-Schiff
1055 (PAS) staining and interstitial fibrosis was assessed with Masson Trichrome staining as
1056 previously described (62, 63). For statistical analysis, at least 10 visual fields of each
1057 specimen were randomly selected and photographed under the microscope (200×,
1058 Olympus BX53), and the positive areas were statistically analyzed with Fiji/ImageJ.

1059 Tubular apoptosis was assessed by Terminal dUTP Nick-End Labeling (TUNEL)
1060 staining with *in Situ* Cell Death Detection Kit (Roche, catalog no. 11684795910) according
1061 to manufacturer's instructions. TUNEL-positive cells/nuclei are quantified as the
1062 percentage (%) of TUNEL and DAPI double-positive cells relative to total cells (DAPI-
1063 positive cells). For statistical analysis, 10 visual fields of each specimen were randomly
1064 selected and photographed with fluorescence microscope (Keyence BZ-X710) and
1065 analyzed with Fiji/ImageJ.


1066 For the immunofluorescence, the kidney slices were subjected to antigen retrieval with
1067 a sodium citrate buffer and permeabilized with 0.3% Triton-X 100 in PBS, blocked with 5%
1068 normal goat serum, and probed with the primary antibody CD31 (Abcam, ab182981).
1069 After washing, the tissue sections were probed with a fluorophore-conjugated secondary
1070 antibody Donkey Anti-Rabbit IgG H&L (Abcam, ab150075). Then, the tissue sections
1071 were photographed with fluorescence microscope (Keyence BZ-X710) and analyzed with
1072 Fiji/ImageJ. Five images per kidney were acquired and the CD31 density (vessel density)
1073 index was calculated by dividing the CD31-positively stained area by the kidney area.

1074 All morphometric analyses were performed by an experienced renal pathologist (L.
1075 Fu) blinded to the experimental procedures.

1076 **Western blotting**

1077 Western blotting was used to confirm the purity of isolated mitochondria protein.
1078 Mitochondria protein extracts from kidney tissue (30 µg per lane) were separated on a
1079 7.5 % SDS-PAGE gel as described previously (66, 67). After blocking for 1 hour at room
1080 temperature with Odyssey Blocking buffer-TBS, the membranes were incubated
1081 overnight with GAPDH and ATP5A antibodies (ab8245 and ab14748, Abcam,

1082 respectively) at 4°C. The membranes were then incubated with Goat anti-Mouse IgG H&L
 1083 (IRDye® 800CW) secondary antibody (ab216772, Abcam) and imaged on an Odyssey
 1084 Imager (Li-Cor).
 1085



1086

1087 **Figure S1. Renal tubular sodium handling is modulated by the application of**
 1088 **decelerating- and accelerating-3rdgen-SMEF *in vivo*.** The effects of 3rdgen-SMEF
 1089 modulation of Na/K Pump activity on sodium handling under basal conditions and during
 1090 a volume challenge were evaluated *in vivo*. **A** shows the urinary flow and sodium
 1091 excretion rates before, during, and after application of *decelerating-3rdgen-SMEF*, which
 1092 was only applied to the left kidney (the right served as a control). **A.i** represents urinary
 1093 flow rates, while **A.ii** represents urinary sodium excretion rates. Prior to applying
 1094 *decelerating-3rdgen-SMEF*, urine flow and sodium excretion rates were essentially the
 1095 same in each kidney. Application of the *decelerating-3rdgen-SMEF* was associated with
 1096 an increase in both parameters only in the treated kidney. When the *deaccelerating-*
 1097 *3rdgen-SMEF* was turned off, all the measured factors returned to basal levels. Data are
 1098 shown as mean ± s.e.m. Repeated measures ANOVA was performed (Asterisks
 1099 represent an analysis with Bonferroni's multiple comparison test. n=7 rats, *p<0.1;
 1100 **P < 0.01; ***P < 0.001; ****P<0.0001;). **B** illustrates renal responses to acute volume
 1101 expansion in the presence and absence of *accelerating-3rdgen-SMEF* (note that 3rdgen-
 1102 SMEF was applied to both kidneys in these experiments). Basal urinary flow rates were
 1103 similar in both groups. Acute volume expansion caused a rapid and profound increase in
 1104 urine flow that peaked within 30 minutes. The flow gradually decreased over the next 120
 1105 minutes as the volume load from the saline bolus was excreted. The animals in which

1106 *accelerating-3rdgen-SMEF* was applied did not see this increase. Urine flow rates had
1107 dipped returned to baseline after 30 minutes. Upon turning off the *accelerating-3rdgen-*
1108 *SMEF*, the urine flow rate rapidly rose to above basal values and remained elevated for
1109 the duration of the experiments. Data are shown as mean \pm s.e.m. The urinary flow rates
1110 measured when the *accelerating-3rdgen-SMEF* was on were compared to the control
1111 group by paired t-test (**P < 0.01; ***P < 0.001; ****P<0.0001; n=5/group)
1112

1113


1114

1115

1116

1117

1118



1119

1120 **Fig. S2. Isolated mitochondria.** A representative western blot of isolated mitochondria
1121 and total tissue lysate. Mitochondrial membrane ATP synthase 5 antibody was used as a
1122 marker for mitochondria. For the detection of potential contaminations, antibody against
1123 GAPDH was also used.

1124



1125 **3rdgen-SMEF treated donor**

1126 **Untreated donor**

1127 **Figure. S3 Representative image for the application of the *accelerating-3rdgen-***
1128 ***SMEF* on discarded human donor kidneys.** The paired control and treated kidneys
1129 were from the same kidney donor. As showed in the image, the left kidney was applied
1130 with *accelerating-3rdgen-SMEF* and the right kidney from the same donor was as
1131 untreated control (n=5 pairs of kidney grafts from 5 kidney donors). The total storage time
was 24 hours.

1132 **Data file S1.** Raw data for all figures where n is less than or equal to 20, including data
1133 for Fig. 1D, Fig. 2Cii-iii and Diii, Fig. 3A, B and C i-iv, Fig. 4A, B, C, D and F, Fig. 5A, B,
1134 C and E, Fig. 6B and fig. S1 A and B.

1135

